Dr. Fessel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2200 Ofarrell St
San Francisco, CA 94115Phone+1 415-833-2000Fax+1 415-833-8715
Education & Training
University of California (San Francisco) School of MedicineInternship, Transitional Year, 1960 - 1961- University of California (San Francisco)/Mount ZionResidency, Internal Medicine, 1957 - 1957
University of London Faculty of MedicineClass of 1955
Certifications & Licensure
CA State Medical License 1962 - 2020
Clinical Trials
- Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection Start of enrollment: 2014 Dec 09
Publications & Presentations
PubMed
- 147 citationsHIV-1 Protease Mutations and Protease Inhibitor Cross-ResistanceSoo-Yon Rhee, Jonathan Taylor, W. Jeffrey Fessel, David Kaufman, William J. Towner
Antimicrobial Agents and Chemotherapy. 2010-10-01 - 17 citationsN88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.Yumi Mitsuya, Mark A. Winters, W. Jeffrey Fessel, Soo-Yon Rhee, Leo B. Hurley
AIDS Research and Human Retroviruses. 2006-12-01 - 14 citationsHIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL.Yumi Mitsuya, Mark A. Winters, W. Jeffrey Fessel, Soo-Yon Rhee, Sally Slome
Journal of Acquired Immune Deficiency Syndromes. 2006-09-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
